Plasma is straw colored, clear liquid component of blood which is basically a protein-salt solution. The red blood cells, white blood cells, and platelets are suspended in the blood plasma. Plasma is 92% water and accounts for 5% of the total human body weight and about 55% of blood volume. Plasma contains more than 100 different proteins including albumin, fibrinogen, immunoglobulins, protease inhibitors, and clotting factors. Plasma plays a vital role in maintaining the blood pressure and exchanging important minerals such as sodium and potassium to maintain proper pH balance in the body. It is obtained by separating the suspended cells and proteins from it. Plasma derivatives contain specific concentrates of plasma protein obtained from blood plasma. These are obtained through a process known as fractionation. Plasma derivatives include albumin, factor VIII and IX, anti-inhibitor coagulation complex (AICC), immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III concentrate. Albumin constitutes the major and important part of plasma protein which is responsible for maintaining the oncotic pressure in blood vessels and has numerous transport functions. Immunoglobulins are responsible for generating an efficient immune response against an infectious disease or pathogen. The blood clotting factors constitute factor VIII and IX which help in blood coagulation.
Blood plasma derivatives have a wide range of clinical applications. These are used in the treatment of various life threatening diseases. Blood plasma derivatives are obtained from blood donors. Advancement and development of better methods for preservation of these blood plasma derivatives along with newer and developed procedures for fractionation fuel the growth of the global blood plasma derivative market. Moreover, rising cases of life threatening diseases such as HIV, hepatitis, and hemophilia create a demand and opportunity in the global blood plasma derivatives market. Furthermore, various government and non-governmental organizations initiatives to conduct and promote blood donation camps has resulted in increase in human blood collection. This is boosting the growth of the global blood plasma derivatives market.
The global blood plasma derivatives market can be segmented based on type, application, end-user, and region. Based on type, the market can be categorized into albumin, anti-inhibitor coagulation complex, factor VIII concentrate, factor IX concentrate, immunoglobulins, including Rh immune globulin, Alpha 1-Proteinase Inhibitor Concentrate and Anti-Thrombin III Concentrate. Based on application, the global blood plasma derivatives market can be segmented into HIV, hemophilia A, hemophilia B, hepatitis B, hepatitis C, bleeding disorders, genetic lung disorders, immune system deficiencies and dysfunctions, shock, trauma, burns, cardiopulmonary needs, Rh incompatibility, transplant recipients, liver conditions, pediatric HIV, and rabies from animal bites. Plasma derived products are also used for treatment of rare diseases such as hereditary angioedema, alpha-1 antitrypsin deficiency, also known as genetic chronic obstructive pulmonary disease (CODP), Kawasaki disease (KD), and congenital fibrinogen deficiency. In terms of end- user, the market can be divided into hospitals, clinics, research institutes, and blood transfusion centers.
In terms of region, the global blood plasma derivatives market can be segmented into North America, Europe, Asia Pacific, and Middle East & Africa. North America is the largest market for blood plasma derivatives. Growing awareness regarding the use and availability of plasma derivatives for treatment of infectious diseases drives the market in North America. Europe is the second largest market for blood plasma derivatives. Advanced research carried out by various health care institutes on safe blood transfusion fuels the growth of the market in Europe. Asia Pacific is expected to be the fastest growing market for blood plasma derivatives during the forecast period.
Key players operating in the global blood plasma derivatives market are Baxter BioScience, Grifols S.A., CSL Behring, ViroPharma, Inc., Talecris Biotherapeutics, Inc., Octapharma, and Fusion Healthcare, among others.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.